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96 Poster Session Ior alternative donors (mismatched-related, haplo-identical and
cord-blood, n 5 27) performed in a single institution since 1/
2001. GF was diagnosed in 25 patients (pts), cumulative incidence
(CI) 5.2% (95%ci 3.5–7.6). GF was determined when ANC had
not reached 0.5  10*9/L by day 21 (primary GF, n 5 21) or
when ANC decreased irreversibly after engraftment (secondary
GF, n 5 4). CI of GF was 2.5%, 6.8% and 23.4% after SCT
from siblings, MUD or alternative donors, respectively (p \
0.001) but was similar following myeloablative or reduced-intensity
conditioning (5.7% and 4.6%, respectively). Pts with a predominant
donor population in chimerism testing were given donor cell boost
with no additional conditioning (n 5 10). Pts with a predominant
host population were given autologous back-up cells (n5 8) or a sec-
ond SCT from a different donor (sibling-1, haplo-3, MUD-1) with
nonmyeloablative conditioning. 18 pts survived. 1 week after sec-
ond graft infusion and are evaluable for engraftment. 16 pts en-
grafted within a median of 10 days (range, 5–15). The probability
and pace of engraftment was similar in the different approaches.
11 pts (44%) were able to be discharged home and 14 died; 2 early
after diagnosis of GF with no intervention, 5 within one week of sec-
ond graft infusion and prior to engraftment, 2 with no engraftment
and 5 early after engraftment from infection (n5 3), organ failure (n
5 1) and GVHD (n 5 1). With a median follow-up of 19 months
(range, 3–68), 6 are alive and 5 additional pts died (relapse-3,
GVHD-1, infection-1). The projected 2-year survival for all pts
was 23% (95%ci 5–41). Interestingly, 4 pts given autologous cells
had donor cell recovery, 1 had spontaneous autologous reconstitu-
tion within 3 weeks, 2 died within 2 months (GVHD-1, infection-1)
with persistent donor cells and 1 remained complete donor until she
relapsed 2 years later. In conclusion, treatment of GF with a chime-
rism directed method can salvage a subset of pts with GF. Reserving
autologous and/or donor backup cells or an alternative donor is ad-
visable in pts at high-risk of GF. The observation of allogeneic re-
covery after autologous boost is intriguing and of unknown
mechanism.260
COMPARISON OF INCIDENCE OF SYSTEMIC VIRAL INFECTION (SVI) AND
INVASIVE FUNGAL INFECTION (IFI) IN CHILDREN RECEIVING BUSUL-
FAN BASED REDUCED INTENSITY ALLOGENEIC STEM CELL TRANS-
PLANT (RIAlloSCT) VS. MYELOABLATIVE AlloSCT (MA-AlloSCT) FOR
MALIGNANT AND NON-MALIGNANT DISEASES
Satwani, P., Freedman, J., Baldinger, L., Guerra, J., van de Ven, C.,
Jin, Z.Z., Garvin, J., George, D., Bradley, M.B., Bhatia, M.,
Schwartz, J., Wolownik, K., Foley, S., Hawks, R., Cairo, M.S. Morgan
Stanley’s Children’s Hospital New York-Presbyterian, Columbia Univer-
sity, New York, NY.
We have previously demonstrated the safety and efficacy of RIAl-
loSCT in pediatric recipients (DelToro/Cairo et al, BMT, 2004;
Bradley/Cairo et al, BMT, 2007). RIAlloSCT in adults is associated
with a significant decrease in early bactermia (Junghanns et al,
BBMT, 2002), but not in incidence of IFI or CMV (Fukuda et al,
Blood 2003; Junghanns et al, Blood 2002). Date is lacking on inci-
dence and timing of SVI and IFI in children undergoing RIAl-
loSCT. We compared the incidence of SVI and IFI in children
receiving busulfan (BU)-based RIAlloSCT (group-A) vs. MA-Al-
loSCT (group-B) for various malignant and non-malignant dis-
eases. Regimens in group-A were BU (6.4–8 mg/kg)/Fludarabine
(FLU) (150–180 mg/m2) 6 ATG (n 5 36) and regimens in
group-B were BU (12.8–16 mg/kg)/FLU (150–180 mg/m2) 6
Alemtuzumab (n 5 17) vs. MA regimen (group-B) consisting of
BU (12.8–16 mg/kg)/Cyclophosphamide (120–200 mg/kg) or Mel-
phalan (135 mg/m2)6 ATG (n5 34). Median age: 7 yrs in group-A
(0.5–21) and 4.5 yrs in group B (0.3–21), respectively. Stem cell
source: UCB (group-A 5 31, group-B 5 20), PBSC (group-A 5
18, group-B5 6), BM (group-A5 4, group-B5 8). Donor source:
HLA-matched sibling (group-A 5 14, group-B 5 8), partially
matched related (group-A 5 3, group-B 5 2), unrelated (group-A
5 37, group-B 5 24). GVHD prophylaxis consisted of tacroli-
mus/MMF for most patients (Osunkwo/Cairo et al, BBMT,
2004). CMV at risk recipients received ganciclovir/foscarnet (Sher-
eck/Cairo et al, PBC, 2006) and most received antifungal prophy-laxis with liposomal amphotericin B until day -100 (Roman/Cairo
et al, PBC, 2007). Median follow-up: 782 days group-A/349 days
group-B. Median time to myeloid engraftment: 19 days group-A
& 20 days group-B. Incidence of aGVHD: 33% group-A/46%
group-B. Incidence of cGVHD: 31% group-A/25% group-B. SVI
were present in 27/53 pts (50%) in group-A and 22/34 pts (64%)
in group-B (p5ns); Table-1. IFI were present in 5/53 pts (9.4%)
in group-A, 5/34 pts (15%) in group-B (p5ns); Table-1. 3 pts
died 1 of RSV pneumonitis in group-A and 1 each of invasive asper-
gillus in group- A and B, respectively. Incidence of mortality sec-
ondary to SVI and IFI was 2/53 pts (3.7%) group-A, 1/34 pts
(2.9%) group-B. The estimated 1 yr OS was 77.7% (CI95: 65.7–
89.4) group-A and 63.8% (CI95: 57.4–80.3, p5ns) group-B. While
the incidence of SVI and IFI was similar in children undergoing RI
vs. MA-AlloSCT, further analysis is required to determine the im-
pact of RI conditioning on timing and mortality of SVI and IFI.
Group-A Group-B
Infection N 5 53 (%) N 5 34 (%)Adenovirus 5 (9.4) 2 (6)
CMV 5 (9.4) 5 (14)
EBV 0 0
RSV 10 (18) 6 (18)
Para-Influenza 4 (8) 5 (14)
Varicella 5 (9.4) 0
HSV 5 (9.4) 2 (6)
Influenza 2 (3.7) 2 (6)
BK-virus 7 (13) 9 (26)
Rota virus 4 (7.5) 2 (6)
Candida spp. 5 (9.4) 1 (3)
Asperigillus 3 (5.6) 0






THE PREVALENCE AND DETERMINANTS OF THE USE OF COMPLEMEN-
TARY AND ALTERNATIVE MEDICINE IN HEMATOPOIETIC STEM CELL
TRANSPLANTATION PATIENTS
Aksoy, S., Kocal, N., Akdogan, S., Ozdemir, E. Hacettepe University In-
stitute of Oncology, Ankara, Turkey.
Background: The aim of this study was to explore the use of
complementary and alternative medicine (CAM) in hematopoietic
stem cell transplantation (HSCT) patients. Methods: A descriptive
survey design was developed. Data was collected through a descrip-
tive questionnaire from 85 patients in outpatient HSCT clinic. Pa-
tients who underwent autologous or allogeneic stem cell
transplantation for hematological malignancies and were at least
100 days post-transplantation were included in this study. Results:
Seventy-two (55 male, 17 female) autologous and 13 (9 male, 4 fe-
male) allogeneic HSCT patients were included in the study. The
median age was 46 (range; 19–80) and median period of time
from the HSCT to evaluation was 24 months (range 4–86).
Thirty-six (42.4%) patients declared the use of some form of
CAM.
Median age of CAM using patients was 36 (range; 19–80) while
the others’ was 50 (range; 23–69) (p 5 0.14).
Patients treated with autologous HSCT reported more frequent
use of some form of CAM than the allogeneic ones (45.8% vs.
%23.1%) (p 5 0.10).
Females (66.7% vs. 34.9%) (p 5 0.01) and higher educated pa-
tients (52.9% vs. 26.5%) (p 5 0.013) used CAM more frequently
than the others. Married patients used CAM less frequently than
the others (35.9% vs. 61.9%) (p 5 0.01).
Herbal medicines and remedies were the most commonly used
CAM therapies. Urtica Dioica, Nigella Sativa and grape seed
were the most commonly used ones. The source of CAM-related in-
formation was mainly friends/family and the media. The majority
used CAM to increase the body’s ability to fight cancer or improve
Poster Session I 97physical and emotional well-being, and many declared that they felt
a beneficial effect from the use of CAM.Conclusions: It is essential
that health professionals explore the use of CAM among their can-
cer patients, educate them about potentially beneficial and proven
therapies in light of the limited available evidence of effectiveness
and potential side effects of CAM.
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PROSPECTIVE MONITORING OF NUTRITIONAL STATUS DURING THE
EARLY PHASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION (HSCT)
Fuji, S.1, Kamiya, S.2, Kim, S.-W.1, Sugiyama, M.2, Fukuda, T.1,
Mori, S.-I.1, Kurosawa, S.1, Yokoyama, H.1, Saito, B.1,
Takahashi, T.1, Heike, Y.1, Tobinai, K.1, Tanosaki, R.1,
Kuwahara, S.2, Takaue, Y.1. 1National Cancer Center Hospital,
Chuo-ku, Tokyo, Japan; 2National Cancer Center Hospital, Chuo-ku,
Tokyo, Japan.
Background: Currently recommended measures of parenteral
nutrition (PN) after HSCT are often associated with hyperglycemia
due to corticosteroids and calcineurin inhibitors, which increases
the risk of infectious complications and mortality. This potential
risk prevents the routine use of PN. In this study, we prospectively
monitored caloric intake, changes in body compartment and bio-
chemical indices, and assessed the correlation between these factors
and clinical outcomes. Methods: Between April 2006 and August
2007, 76 patients received allogeneic HSCT in our institute. We ex-
cluded 16 patients due to progressive disease, graft failure and obvi-
ous fluid retention including engraftment syndrome, heart failure,
renal failure and liver failure. The remaining 60 patients were cate-
gorized according to the mean caloric intake from the beginning of
conditioning to day 56 or discharge: group 1 mean caloric intake
was\ basal energy expenditure (BEE, n 5 17), group 2 1.0–1.3 
BEE (n 5 34), and group 3 . 1.3  BEE (n 5 9). The median
age was 49.5 years. There were no statistically significant differences
in the proportion of conventional or reduced-intensity conditioning
regimens among the 3 groups. Endpoints were changes in the actual
resting energy expenditure (REE), body weight (BW) and other in-
dicators of body compartments including muscle, fat and water
weight, biochemical indices (total protein, albumin, pre-albumin
and cholinesterase), clinical events including GVHD and infectious
diseases, and length of hospital stay. Results: REE was within the
range 1.0–1.2BEE in all 3 groups. In group 1, BW (7.5%), muscle
(9.1%) and fat (10.8%) were significantly decreased, whereas no sta-
tistically significant loss of BW, muscle and fat was documented in
group 2 or group 3. There was a significant correlation between
weight loss and muscle loss (r5 0.89, P\0.001), but no differences
were found in the biochemical indices, or the incidences of GVHD
and infectious diseases among the 3 groups. The length of the hos-
pital stay after HSCT was significantly longer in group 1 compared
with the other groups (74 vs 55 days, P 5 0.03). Conclusion: Pro-
spective monitoring revealed that low caloric intake was associated
with a significant weight loss, muscle loss and longer length of hos-
pitalization. Our data suggest that the patient’s clinical outcome will
be improved if the caloric intake during the early phase after alloge-
neic HSCT is maintained over 1.0  BEE.263
CURRENT EPIDEMIOLOGY OF ORAL CANDIDA COLONIZATION IN PA-
TIENTS WITH HEMATOLOGIC MALIGNANCIES UNDERGOING HEMATO-
POIETIC STEM CELL TRANSPLANTATION: A LONGITUDINAL,
PROSPECTIVE STUDY
Toro, J.J.1,2, Westbrook, S.D.1,2, Kirkpatrick, W.R.2, Fothergill, A.W.2,
Patterson, T.F.1,2, Redding, S.W.1,2, Freytes, C.O.1,2. 1South Texas Vet-
erans Health Care System, San Antonio, TX; 2University of Texas
Health Science Center at San Antonio, San Antonio, TX.
Background: The epidemiology of yeast colonization and sys-
temic infection in hematopoietic stem cell transplant (HSCT) re-
cipients has changed substantially in recent years. Although
Candida albicans remains the most common yeast pathogen, non-al-
bicans Candida species are increasingly being encountered. The rou-
tine use of fluconazole and its successful use in preventing C.albicans-related colonization and infection have caused a shift to
more resistant yeast species that represent a new clinical challenge.
Objective: To follow the evolution of Candida oral colonization
throughout HSCT therapy, employing fluconazole prophylaxis,
in order to determine the current epidemiology of resistance to
this agent. Methods: In a longitudinal, prospective study we evalu-
ated a total of 55 patients with hematologic malignancies who un-
derwent HSCT (46 autologous and 9 allogeneic) and received
fungal prophylaxis with fluconazole 400 mg PO daily starting the
first day of the conditioning regimen. Samples to assess oralCandida
colonization were collected, using the swish and spit technique,
prior to the start of fluconazole prophylaxis, on transplant day
and on a weekly basis until hospital discharge. Candida species iden-
tification was performed via CHROMagar Candida and germ tube
with confirmation using API-20C. MICs were determined using
CLSI methodology by The University of Texas Health Science
Center at San Antonio Fungus Testing Laboratory. Strain differen-
tiation in selected patients was performed by PCR analysis of each
isolate.Results:Oral colonization byCandida species was identified
in 36 of 55 (65%) patients during the study period (Table 1). Thirty-
two of 36 (89%) of these patients had a positive culture during the
initial evaluation and 26 of 36 (81%) patients had more than one
positive culture despite the use of fluconazole. Seven of 55 (13%)
patients had mixed cultures. Candida species with reduced suscepti-
bility or resistance to fluconazole were seen in 10 of 55 (18%) pa-
tients. Conclusions: Despite fungal prophylaxis with systemic
fluconazole, oral colonization by Candida species remains common
in HSCT recipients. Non-Candida albicans species with decreased
susceptibility to fluconazole continue to emerge. These data suggest
that a longitudinal surveillance with oral sampling, in patients un-
dergoing HSCT, is a good mechanism to identify patients at risk
for systemic infections with fluconazole resistant yeast, and should
be further evaluated.
Table 1. Oral fungal species associated with the HSCT
Yeast Species Total PercentCandida albicans 25 57
Candida glabrata * 12 27
Candida tropicalis 3 7
Candida dubliniensis * 1 2
Candida famata 1 2
Candida krusei * 1 2
Candida parapsilosis 1 2
Saccharomyces cerevisiae 1 2*Of the 10 patients with reduced susceptibility or resistance to flu-
conazole 8 were colonized by C. glabrata, 1 by C. dubliniensis, and 1
byC. krusei . Two of the 8 patients colonized byC. glabratawere col-
onized simultaneously by 2 different strains.264
THE POPSICKLE WITH STRAWBERRY AROMA REDUCES INFUSION-RE-
LATED NAUSEA AND VOMITING DURING THE INFUSION OF CRYOPRE-
SERVED PERIPHERAL BLOOD STEM CELLS
Akgedik, K., Akdogan, S., Aksoy, S., Ozdemir, E. Hacettepe University
Institute of Oncology, Ankara, Turkey.
Background: The aim of this study was to explore the effect of
popsickle with strawberry aroma on the infusion-related toxicity
of cryopreserved autologous peripheral blood stem cells (PBSC).
Methods: We compared two groups of adult patients receiving
popsickle with strawberry aroma during infusion or not to assess
the incidences of adverse events occurring during infusion. All pa-
tients received granisetron 2  3 mg iv, lorezepam 6  1 mg po
for prophylaxis of the nausea and vomiting during conditioning
phase and infusion day. The patients had no evidence of nausea or
vomiting prior to cryopreserved PBSC infusion. The patients
with ongoing nausea or vomiting owing to conditioning regimens
and/or receiving additional anti-emetics were excluded from the
study. Results: Forty-five patients (median age 45, range; 17–75)
were given popsickle with strawberry aroma during infusion and
